The National Advertising Division refers wellness brand HigherDose to federal regulators following refusal to substantiate marketing claims

The National Advertising Division (NAD), the advertising industry’s primary self-regulatory body and a division of BBB National Programs, announced on Tuesday that it will refer wellness brand HigherDose to federal and state regulatory authorities. The decision follows the company’s repeated refusal to participate in two separate inquiries regarding the substantiation of performance claims made for its popular Red Light Hat and Red Light Face Mask products. This rare move marks a significant escalation in the ongoing oversight of the rapidly expanding wellness-tech sector.

The Scope of the Disputed Claims

The inquiries, initiated by the NAD as part of its routine, ongoing monitoring program, centered on specific health and beauty benefits touted by HigherDose in its marketing materials. The NAD sought to examine the scientific evidence supporting the brand’s assertions.

Regarding the Red Light Hat, the NAD flagged several express and implied claims, including that the device supports healthy hair growth, increases blood flow, rejuvenates hair follicles, reduces shedding, and strengthens hair roots. For the Red Light Face Mask, the NAD sought evidence to support claims that the device reduces fine lines and wrinkles, improves the skin barrier, increases firmness, and boosts overall skin hydration.

These types of "performance claims"—assertions that a product will deliver a specific physiological result—are held to high standards under Federal Trade Commission (FTC) guidelines. Advertisers are required to possess a "reasonable basis" for such claims, which typically involves competent and reliable scientific evidence. By failing to participate in the NAD’s review process, HigherDose effectively bypassed the opportunity to provide that evidence to an independent arbiter, leading the NAD to escalate the matter to the authorities.

The Mechanics of the Self-Regulatory Referral

The NAD operates as an industry-funded mechanism designed to resolve advertising disputes without the need for litigation. It serves as a filter that helps ensure transparency and accuracy in advertising, maintaining consumer trust in the marketplace. While the process is voluntary, the consequence for non-compliance or non-participation is a referral to the FTC or state-level regulators.

Annie M. Ugurlayan, assistant director of the National Advertising Division, noted the gravity of the situation during an interview regarding the referral. "We identified two specific products with pretty strong performance claims, and the advertiser did not want to participate in the self-regulatory process," Ugurlayan explained.

She emphasized that referrals are statistically rare. "Most companies do participate. We have an over 90 percent compliance rate, so it is really a handful of cases that we have every year where they do result in referrals," she added. By moving this case to the FTC, the FDA, and the relevant State Attorneys General, the NAD is signaling that the claims in question are significant enough to warrant government scrutiny.

HigherDose’s Stance and the Voluntary Process

In response to the announcement, a representative for HigherDose issued a statement defending the company’s decision. "HigherDose stands behind its Red Light Hat and Red Light Face Mask. NAD’s process is voluntary. After careful consideration, we decided not to take part in this particular process. That decision does not reflect any doubt about our products or our claims, and NAD has made no finding to the contrary."

The company’s position highlights a fundamental tension in the wellness industry: the distinction between "voluntary" industry standards and legal requirements. While the NAD process is technically optional, the refusal to engage is often interpreted by industry watchdogs as a red flag, as it prevents the public and consumers from assessing the validity of product claims through an objective, third-party lens.

The Growth of the Wellness-Tech Sector and Regulatory Oversight

The wellness-tech industry, which includes red light therapy devices, at-home lasers, and smart-wearables, has seen exponential growth over the last five years. According to industry data, the global red light therapy market is projected to reach several billion dollars by 2030, driven by the democratization of beauty and recovery technologies that were previously only available in professional clinical settings.

However, this rapid commercialization has outpaced regulatory oversight. Because many of these devices straddle the line between "wellness products" and "medical devices," they often fall into a gray area of oversight. The FDA regulates medical devices, but many manufacturers market their goods as "general wellness" products to avoid the rigorous and costly clinical trial requirements associated with FDA 510(k) clearance or PMA (Premarket Approval).

The NAD has increasingly turned its attention to this sector. Ugurlayan noted that the organization has evaluated various red light therapy devices in the past and continues to monitor the wellness industry as a high-priority area. The intent is not necessarily to ban such products, but to ensure that consumers are not misled by claims of "clinical-grade" results that may lack underlying peer-reviewed studies.

Historical Context and Precedents

The HigherDose referral is part of a broader trend of increased scrutiny in the beauty and wellness space. In 2023, the NAD handled a high-profile case involving Huda Beauty, where the brand voluntarily dropped claims regarding its "Easy Bake Setting Spray" following a challenge from Charlotte Tilbury Beauty. That case, which was fast-tracked by the NAD, demonstrated the effectiveness of the process when companies are willing to participate in the dialogue.

When companies refuse to participate, the resulting referral to the FTC can lead to formal investigations, civil penalties, and mandated corrective advertising. In the current regulatory climate, the FTC has been particularly aggressive regarding the substantiation of health claims. Under the current administration, the commission has demonstrated a heightened interest in "deceptive marketing," especially in the supplement and wellness markets, where vulnerable consumers may be persuaded by claims of anti-aging, hair regrowth, or skin rejuvenation.

Analysis: Implications for the Industry

The decision to refer HigherDose to regulators suggests a shift in how the NAD approaches brands that opt out of its proceedings. By explicitly naming the FTC and the FDA, the NAD is effectively inviting federal agencies to perform the audit that the brand refused to facilitate.

For the wellness industry, the implications are clear: the era of "unsubstantiated marketing" is facing significant pressure. Companies that market advanced technology—such as LED-based skincare or hair growth devices—are increasingly being held to the same standards as pharmaceutical and medical device manufacturers.

If federal authorities choose to investigate, they will look for rigorous clinical trials, typically randomized, double-blind, placebo-controlled studies. If HigherDose or similar companies cannot produce this documentation, they may face forced changes to their marketing copy, fines, or even the withdrawal of products from the market.

Moving Forward: Consumer and Market Impact

For consumers, the NAD’s move serves as a reminder to exercise caution when encountering high-impact health claims in digital marketing. While many red light devices do utilize technology with established biological mechanisms (such as photobiomodulation), the specific results promised in marketing copy often exceed what the science can definitively prove for a specific device.

As the matter now shifts from the desk of the NAD to federal regulators, the industry will be watching closely to see how the FTC responds. If the FTC takes action, it could set a powerful precedent, reinforcing the idea that "wellness" is not a loophole for avoiding the legal requirements of truth-in-advertising. Until then, the dispute between HigherDose and the NAD remains a pivotal case study in the power of industry self-regulation and the limits of voluntary compliance in a high-stakes, high-growth market.

The ultimate outcome of the referral remains at the discretion of the regulatory agencies. While the NAD cannot compel HigherDose to change its marketing, a formal letter of inquiry or a subpoena from the FTC would carry significantly more legal weight, potentially compelling the company to reveal the internal data it currently cites as its justification for refusing the NAD’s review. For now, the case remains an open question regarding the intersection of modern wellness marketing and the mandates of consumer protection.